| Literature DB >> 25187092 |
Abstract
Canagliflozin is a new drug in class of sodium-glucose cotransporter 2 inhibitors used for treatment of type 2 diabetes mellitus. We describe a patient who developed moderately severe acute pancreatitis as an untoward consequence after being initiated on this drug. To the best of our knowledge, this is the first reported case of canagliflozin-associated acute pancreatitis in clinical literature.Entities:
Mesh:
Substances:
Year: 2016 PMID: 25187092 DOI: 10.1097/MJT.0000000000000135
Source DB: PubMed Journal: Am J Ther ISSN: 1075-2765 Impact factor: 2.688